LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Riaz, Moeen"
  2. AU="Ogaki, W"
  3. AU="Brown, Anna"
  4. AU="Nakonezny, Paul A"
  5. AU="Sun, Yuan-Yuan"
  6. AU="Palazuelos Molinero, Jorge"
  7. AU="Papamikos, Vassilios"
  8. AU="Toledano-Osorio, Manuel"
  9. AU="Aston, Kenneth"
  10. AU="Crowe, Remle"
  11. AU="El-Yazbi, Amira F"
  12. AU=Wong Kai Yau AU=Wong Kai Yau
  13. AU="Wais, Verena"
  14. AU=Barbieri Lavinia AU=Barbieri Lavinia
  15. AU=McKay Jennifer S
  16. AU="Frohn, Marina"
  17. AU="Blaksley, C"
  18. AU="Heri Hermasyah"
  19. AU="Charlier, Filip"
  20. AU="Mihalopoulos, N"
  21. AU="Fernandez, S Gomez"

Suchergebnis

Treffer 1 - 10 von insgesamt 52

Suchoptionen

  1. Artikel: Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration.

    Riaz, Moeen / Baird, Paul N

    Neural regeneration research

    2017  Band 12, Heft 4, Seite(n) 584–585

    Sprache Englisch
    Erscheinungsdatum 2017-04-07
    Erscheinungsland India
    Dokumenttyp Journal Article
    ZDB-ID 2388460-5
    ISSN 1876-7958 ; 1673-5374
    ISSN (online) 1876-7958
    ISSN 1673-5374
    DOI 10.4103/1673-5374.205094
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Genetics in Retinal Diseases.

    Riaz, Moeen / Baird, Paul N

    Developments in ophthalmology

    2016  Band 55, Seite(n) 57–62

    Abstract: The phenotypic presentation of retinal diseases is typically underpinned by the presence of genetic variation represented by either polymorphic changes, mutations, copy number variations or epigenetic changes. Retinal dystrophies can broadly be divided ... ...

    Abstract The phenotypic presentation of retinal diseases is typically underpinned by the presence of genetic variation represented by either polymorphic changes, mutations, copy number variations or epigenetic changes. Retinal dystrophies can broadly be divided into two forms, either monogenic (single-gene) or complex (multifactorial) diseases. Recent advances in molecular techniques such as genome-wide association studies and next-generation sequencing have revolutionized the discovery of genetic variants associated with different retinal disorders, including retinitis pigmentosa and age-related macular degeneration. Understanding the genetic profile of the disease not only helps in diagnostics but also in gene therapy, as recently shown for Leber's congenital amaurosis. Following the elucidation of many genetic features of retinal diseases, the task is now to make sense of this large amount of data to better understand as well as experimentally prove the physiological process of the retinal disease genes and the mechanisms behind the diseases. This in turn will lead to improved gene-based therapies and personalize treatments for patients.
    Mesh-Begriff(e) DNA Copy Number Variations ; Genetic Therapy ; Genome-Wide Association Study ; Humans ; Phenotype ; Retinal Diseases/genetics ; Retinal Diseases/therapy
    Sprache Englisch
    Erscheinungsdatum 2016
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ISSN 1662-2790 ; 0250-3751
    ISSN (online) 1662-2790
    ISSN 0250-3751
    DOI 10.1159/000431142
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.

    Selvadurai, Maria V / Riaz, Moeen / Xie, Sophia / Tonkin, Andrew M / McNeil, John J / Lacaze, Paul / Hamilton, Justin R

    Thrombosis and haemostasis

    2021  Band 122, Heft 7, Seite(n) 1130–1138

    Abstract: Background:  Protease-activated receptor 4 (PAR4) is a platelet thrombin receptor important for thrombosis and a target of antiplatelet drug development. A frequently occurring single-nucleotide polymorphism (rs773902) causes a PAR4 sequence variant ( ... ...

    Abstract Background:  Protease-activated receptor 4 (PAR4) is a platelet thrombin receptor important for thrombosis and a target of antiplatelet drug development. A frequently occurring single-nucleotide polymorphism (rs773902) causes a PAR4 sequence variant (NC_000019.10:p.Ala120Thr) whereby platelets from Thr120-expressing individuals are hyperresponsive to PAR4 agonists versus platelets from Ala120-expressing individuals. However, whether this enhanced platelet responsiveness translates to increased thrombotic risk or decreased bleeding risk remains unknown.
    Objectives:  This article examines the association of rs773902 with adjudicated cardiovascular events and aspirin use in a randomized trial population of healthy older individuals.
    Methods:  We analyzed 13,547 participants in the ASPirin in Reducing Events in the Elderly trial. Participants had no previous cardiovascular events at enrollment and were randomized to either 100 mg daily aspirin or placebo for a median follow-up of 4.7 years. Total genotypes were 8,761 (65%) GG (Ala120 variant), 4,303 (32%) heterozygotes, and 483 (4%) AA (Thr120 variant). Cox proportional hazard regression tested the relationship between rs773902 and thrombotic events (major adverse cardiovascular events [MACE] and ischemic stroke [IS]) and bleeding (major hemorrhage [MHEM] and intracranial bleeding [ICB]).
    Results:  No statistically significant association was observed overall or by treatment group between rs773902 and any thrombotic or bleeding event examined. Further, there was no significant interaction between rs773902 and treatment for any of MACE, IS, MHEM, or ICB.
    Conclusion:  This post hoc analysis of a prospective cohort study suggests that, despite sensitizing platelet activation, the rs773902 PAR4 variant is not associated with thrombotic cardiovascular or bleeding events in a healthy older population.
    Mesh-Begriff(e) Aged ; Aspirin/administration & dosage ; Blood Platelets/physiology ; Hemorrhage/drug therapy ; Humans ; Incidence ; Platelet Aggregation ; Platelet Aggregation Inhibitors/administration & dosage ; Prospective Studies ; Receptor, PAR-1/genetics ; Receptors, Thrombin/genetics ; Thrombosis/drug therapy ; Thrombosis/epidemiology ; Thrombosis/genetics
    Chemische Substanzen Platelet Aggregation Inhibitors ; Receptor, PAR-1 ; Receptors, Thrombin ; protease-activated receptor 4 (JWE1M73YZN) ; Aspirin (R16CO5Y76E)
    Sprache Englisch
    Erscheinungsdatum 2021-12-01
    Erscheinungsland Germany
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/a-1711-1395
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Response to Veenstra et al.

    Lacaze, Paul / Tiller, Jane / Bao, Yining / Riaz, Moeen / Winship, Ingrid / Zhang, Lei

    Genetics in medicine : official journal of the American College of Medical Genetics

    2019  Band 21, Heft 12, Seite(n) 2842–2843

    Mesh-Begriff(e) Cost-Benefit Analysis ; Humans ; Metagenomics ; Young Adult
    Sprache Englisch
    Erscheinungsdatum 2019-07-15
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 1455352-1
    ISSN 1530-0366 ; 1098-3600
    ISSN (online) 1530-0366
    ISSN 1098-3600
    DOI 10.1038/s41436-019-0581-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Implementation of public health genomics in Pakistan.

    Riaz, Moeen / Tiller, Jane / Ajmal, Muhammad / Azam, Maleeha / Qamar, Raheel / Lacaze, Paul

    European journal of human genetics : EJHG

    2019  Band 27, Heft 10, Seite(n) 1485–1492

    Abstract: There has been considerable recent progress in the implementation of public health genomics policy throughout the developed world. However, in the developing world, genetic services still remain limited, or unavailable to most. Here, we discuss ... ...

    Abstract There has been considerable recent progress in the implementation of public health genomics policy throughout the developed world. However, in the developing world, genetic services still remain limited, or unavailable to most. Here, we discuss challenges and opportunities related to the implementation of public health genomics in developing countries. We focus on Pakistan, a country with one of the world's highest rates of inter-family marriages and prevalence of inherited genetic conditions. Pakistan still lacks a national newborn screening programme, clinical genetic testing services, or public health genomics framework. The medical infrastructure in Pakistan, characterized by limited publicly-funded health services and a significant burden of infectious disease, may contribute to de-prioritization of genetic health services. In addition, there are a number of societal, cultural and religious factors to consider. Recently a number of large research studies have been conducted in populations of Pakistani descent, mostly in collaboration with major US, UK and European institutions. Some of these have yielded high-impact scientific findings, but have yet to translate into public health outcomes in Pakistan. Before the benefits of genomics can be realized in developing countries, the first initial steps towards strategic prioritization, resourcing, and long-term goal setting are required. We propose some practical recommendations and possible first steps forward.
    Mesh-Begriff(e) Developed Countries ; Developing Countries ; Genomics/legislation & jurisprudence ; Genomics/methods ; Global Health ; Health Plan Implementation ; Health Policy ; Humans ; Pakistan ; Public Health/legislation & jurisprudence ; Public Health/methods ; Public Health Surveillance ; Research
    Sprache Englisch
    Erscheinungsdatum 2019-05-17
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 1141470-4
    ISSN 1476-5438 ; 1018-4813
    ISSN (online) 1476-5438
    ISSN 1018-4813
    DOI 10.1038/s41431-019-0428-z
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians.

    Jadhao, Sudhir / Davison, Candice / Roulis, Eileen V / Lee, Simon / Lacaze, Paul / Riaz, Moeen / McNeil, John J / Thomas, David M / Pecheniuk, Natalie M / Hyland, Catherine A / Flower, Robert L / Nagaraj, Shivashankar H

    Blood advances

    2022  Band 6, Heft 15, Seite(n) 4593–4604

    Abstract: There have been no comprehensive studies of a full range of blood group polymorphisms within the Australian population. This problem is compounded by the absence of any databases carrying genomic information on chronically transfused patients and low ... ...

    Abstract There have been no comprehensive studies of a full range of blood group polymorphisms within the Australian population. This problem is compounded by the absence of any databases carrying genomic information on chronically transfused patients and low frequency blood group antigens in Australia. Here, we use RBCeq, a web server-based blood group genotyping software, to identify unique blood group variants among Australians and compare the variation detected vs global data. Whole-genome sequencing data were analyzed for 2796 healthy older Australians from the Medical Genome Reference Bank and compared with data from 1000 Genomes phase 3 (1KGP3) databases comprising 661 African, 347 American, 503 European, 504 East Asian, and 489 South Asian participants. There were 661 rare variants detected in this Australian sample population, including 9 variants that had clinical associations. Notably, we identified 80 variants that were computationally predicted to be novel and deleterious. No clinically significant rare or novel variants were found associated with the genetically complex ABO blood group system. For the Rh blood group system, 2 novel and 15 rare variants were found. Our detailed blood group profiling results provide a starting point for the creation of an Australian blood group variant database.
    Mesh-Begriff(e) Asians ; Australia/epidemiology ; Blood Group Antigens/genetics ; Humans ; Polymorphism, Single Nucleotide ; United States ; Whole Genome Sequencing/methods
    Chemische Substanzen Blood Group Antigens
    Sprache Englisch
    Erscheinungsdatum 2022-04-15
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022007505
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Genomic Risk Score for Advanced Osteoarthritis in Older Adults.

    Lacaze, Paul / Wang, Yuanyuan / Polekhina, Galina / Bakshi, Andrew / Riaz, Moeen / Owen, Alice / Franks, Angus / Abidi, Jawad / Tiller, Jane / McNeil, John / Cicuttini, Flavia

    Arthritis & rheumatology (Hoboken, N.J.)

    2022  Band 74, Heft 9, Seite(n) 1480–1487

    Abstract: Objective: Prevention of osteoarthritis (OA) remains important, as there are no disease-modifying treatments. A personalized approach has the potential to better target prevention strategies. In the present study, we used recently identified genetic ... ...

    Abstract Objective: Prevention of osteoarthritis (OA) remains important, as there are no disease-modifying treatments. A personalized approach has the potential to better target prevention strategies. In the present study, we used recently identified genetic risk variants from genome-wide association analysis for advanced OA to calculate polygenic risk scores (PRS) for knee and hip OA and assessed PRS performance in an independent population of older community-dwelling adults.
    Methods: PRS were calculated in 12,093 individuals of European genetic descent ages ≥70 years who were enrolled in the Aspirin in Reducing Events in the Elderly trial. The outcome measure was knee and hip replacement (hospitalizations during the trial and self-reported joint replacements before enrollment). PRS were considered as continuous (per SD) and categorical (low risk [0-20%], medium risk [21-80%], high risk [81-100%]) variables. Logistic regression was used to examine associations between PRS and risk of joint replacement, adjusted for age, sex, body mass index, and socioeconomic status.
    Results: Among the participants, 1,422 (11.8%) had knee replacements and 1,297 (10.7%) had hip replacements. PRS (per SD) were associated with a risk of knee replacement (odds ratio [OR] 1.13 [95% confidence interval (95% CI) 1.07-1.20]) and hip replacement (OR 1.23 [95% CI 1.16-1.30]). Participants with high PRS had an increased risk of knee replacement (OR 1.44 [95% CI 1.20-1.73]) and hip replacement (OR 1.88 [95% CI 1.56-2.26]), compared to those with low PRS. Associations were stronger for PRS and hip replacement risk in women than in men. Associations were similar in sensitivity analyses that examined joint replacements before and during the trial separately.
    Conclusion: PRS have the potential to improve prevention of severe knee and hip OA by providing a personalized approach and identifying individuals who may benefit from early intervention.
    Mesh-Begriff(e) Aged ; Arthroplasty, Replacement, Hip ; Female ; Genome-Wide Association Study ; Genomics ; Humans ; Male ; Osteoarthritis, Hip/epidemiology ; Osteoarthritis, Hip/genetics ; Osteoarthritis, Hip/surgery ; Osteoarthritis, Knee/epidemiology ; Osteoarthritis, Knee/genetics ; Osteoarthritis, Knee/surgery ; Risk Factors
    Sprache Englisch
    Erscheinungsdatum 2022-07-23
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42156
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes.

    Lacaze, Paul / Bakshi, Andrew / Riaz, Moeen / Polekhina, Galina / Owen, Alice / Bhatia, Harpreet S / Natarajan, Pradeep / Wolfe, Rory / Beilin, Lawrence / Nicholls, Stephen J / Watts, Gerald F / McNeil, John J / Tonkin, Andrew M / Tsimikas, Sotirios

    Journal of the American College of Cardiology

    2022  Band 80, Heft 14, Seite(n) 1287–1298

    Abstract: Background: The role of aspirin in reducing lipoprotein(a)-mediated atherothrombotic events in primary prevention is not established.: Objectives: This study sought to assess whether low-dose aspirin benefits individuals with elevated plasma ... ...

    Abstract Background: The role of aspirin in reducing lipoprotein(a)-mediated atherothrombotic events in primary prevention is not established.
    Objectives: This study sought to assess whether low-dose aspirin benefits individuals with elevated plasma lipoprotein(a)-associated genotypes in the setting of primary prevention.
    Methods: The study analyzed 12,815 genotyped individuals ≥70 years of age of European ancestry and without prior cardiovascular disease events enrolled in the ASPREE (ASPirin in Reducing Events in the Elderly) randomized controlled trial of 100 mg/d aspirin. We defined lipoprotein(a)-associated genotypes using rs3798220-C carrier status and quintiles of a lipoprotein(a) genomic risk score (LPA-GRS). We tested for interaction between genotypes and aspirin allocation in Cox proportional hazards models for incidence of major adverse cardiovascular events (MACE) and clinically significant bleeding. We also examined associations in the aspirin and placebo arms of the trial separately.
    Results: During a median 4.7 years (IQR: 3.6-5.7 years) of follow-up, 435 MACE occurred, with an interaction observed between rs3798220-C and aspirin allocation (P = 0.049). rs3798220-C carrier status was associated with increased MACE risk in the placebo group (HR: 1.90; 95% CI: 1.11-3.24) but not in the aspirin group (HR: 0.54; 95% CI: 0.17-1.70). High LPA-GRS (vs low) was associated with increased MACE risk in the placebo group (HR: 1.70; 95% CI: 1.14-2.55), with risk attenuated in the aspirin group (HR: 1.41; 95% CI: 0.90-2.23), but the interaction was not statistically significant. In all participants, aspirin reduced MACE by 1.7 events per 1,000 person-years and increased clinically significant bleeding by 1.7 events per 1,000 person-years. However, in the rs3798220-C and high LPA-GRS subgroups, aspirin reduced MACE by 11.4 and 3.3 events per 1,000 person-years respectively, without significantly increased bleeding risk.
    Conclusions: Aspirin may benefit older individuals with elevated lipoprotein(a) genotypes in primary prevention.
    Mesh-Begriff(e) Aged ; Aspirin/therapeutic use ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/genetics ; Cardiovascular Diseases/prevention & control ; Genotype ; Humans ; Lipoprotein(a)/genetics ; Primary Prevention
    Chemische Substanzen Lipoprotein(a) ; Aspirin (R16CO5Y76E)
    Sprache Englisch
    Erscheinungsdatum 2022-10-04
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 605507-2
    ISSN 1558-3597 ; 0735-1097
    ISSN (online) 1558-3597
    ISSN 0735-1097
    DOI 10.1016/j.jacc.2022.07.027
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel: The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population

    Selvadurai, Maria V. / Riaz, Moeen / Xie, Sophia / Tonkin, Andrew M. / McNeil, John J. / Lacaze, Paul / Hamilton, Justin R.

    Thrombosis and Haemostasis

    2021  Band 122, Heft 07, Seite(n) 1130–1138

    Abstract: Background: Protease-activated receptor 4 (PAR4) is a platelet thrombin receptor important for thrombosis and a target of antiplatelet drug development. A frequently occurring single-nucleotide polymorphism (rs773902) causes a PAR4 sequence variant ( ... ...

    Abstract Background: Protease-activated receptor 4 (PAR4) is a platelet thrombin receptor important for thrombosis and a target of antiplatelet drug development. A frequently occurring single-nucleotide polymorphism (rs773902) causes a PAR4 sequence variant (NC_000019.10:p.Ala120Thr) whereby platelets from Thr120-expressing individuals are hyperresponsive to PAR4 agonists versus platelets from Ala120-expressing individuals. However, whether this enhanced platelet responsiveness translates to increased thrombotic risk or decreased bleeding risk remains unknown.
    Objectives: This article examines the association of rs773902 with adjudicated cardiovascular events and aspirin use in a randomized trial population of healthy older individuals.
    Methods: We analyzed 13,547 participants in the ASPirin in Reducing Events in the Elderly trial. Participants had no previous cardiovascular events at enrollment and were randomized to either 100 mg daily aspirin or placebo for a median follow-up of 4.7 years. Total genotypes were 8,761 (65%) GG (Ala120 variant), 4,303 (32%) heterozygotes, and 483 (4%) AA (Thr120 variant). Cox proportional hazard regression tested the relationship between rs773902 and thrombotic events (major adverse cardiovascular events [MACE] and ischemic stroke [IS]) and bleeding (major hemorrhage [MHEM] and intracranial bleeding [ICB]).
    Results: No statistically significant association was observed overall or by treatment group between rs773902 and any thrombotic or bleeding event examined. Further, there was no significant interaction between rs773902 and treatment for any of MACE, IS, MHEM, or ICB.
    Conclusion: This post hoc analysis of a prospective cohort study suggests that, despite sensitizing platelet activation, the rs773902 PAR4 variant is not associated with thrombotic cardiovascular or bleeding events in a healthy older population.
    Schlagwörter platelets ; thrombosis ; hemostasis ; protease-activated receptors ; thrombin
    Sprache Englisch
    Erscheinungsdatum 2021-12-01
    Verlag Georg Thieme Verlag KG
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/a-1711-1395
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts.

    Downie, Jonathan M / Riaz, Moeen / Xie, Jing / Lee, Minyi / Chan, Andrew T / Gibbs, Peter / Orchard, Suzanne G / Mahady, Suzanne E / Sebra, Robert P / Murray, Anne M / Macrae, Finlay / Schadt, Eric / Woods, Robyn L / McNeil, John J / Lacaze, Paul / Gala, Manish

    Cancer prevention research (Philadelphia, Pa.)

    2022  Band 15, Heft 8, Seite(n) 509–519

    Abstract: MUTYH carriers have an increased colorectal cancer risk in case-control studies, with loss of heterozygosity (LOH) as the presumed mechanism. We evaluated cancer risk among carriers in a prospective, population-based cohort of older adults. In addition, ... ...

    Abstract MUTYH carriers have an increased colorectal cancer risk in case-control studies, with loss of heterozygosity (LOH) as the presumed mechanism. We evaluated cancer risk among carriers in a prospective, population-based cohort of older adults. In addition, we assessed if cancers from carriers demonstrated mutational signatures (G:C>T:A transversions) associated with early LOH. We calculated incident risk of cancer and colorectal cancer among 13,131 sequenced study participants of the ASPirin in Reducing Events in the Elderly cohort, stratified by sex and adjusting for age, smoking, alcohol use, BMI, polyp history, history of cancer, and aspirin use. MUTYH carriers were identified among 13,033 participants in The Cancer Genome Atlas and International Cancer Genome Consortium, and somatic signatures of cancers were analyzed. Male MUTYH carriers demonstrated an increased risk for overall cancer incidence [multivariable HR, 1.66; 95% confidence interval (CI), 1.03-2.68; P = 0.038] driven by increased colorectal cancer incidence (multivariable HR, 3.55; 95% CI, 1.42-8.78; P = 0.007), as opposed to extracolonic cancer incidence (multivariable HR, 1.40; 95% CI, 0.81-2.44; P = 0.229). Female carriers did not demonstrate increased risk of cancer, colorectal cancer, or extracolonic cancers. Analysis of mutation signatures from cancers of MUTYH carriers revealed no significant contribution toward early mutagenesis from widespread G:C>T:A transversions among gastrointestinal epithelial cancers. Among cancers from carriers, somatic transversions associated with base-excision repair deficiency are uncommon, suggestive of diverse mechanisms of carcinogenesis in carriers compared with those who inherit biallelic MUTYH mutations.
    Prevention relevance: Despite absence of loss of heterozygosity in colorectal cancers, elderly male MUTYH carriers appeared to be at increased of colorectal cancer.
    Mesh-Begriff(e) Aged ; Aspirin ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms/genetics ; DNA Glycosylases/genetics ; Female ; Genetic Predisposition to Disease ; Genomics ; Humans ; Male ; Mutation ; Prospective Studies
    Chemische Substanzen DNA Glycosylases (EC 3.2.2.-) ; Aspirin (R16CO5Y76E)
    Sprache Englisch
    Erscheinungsdatum 2022-05-24
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2434717-6
    ISSN 1940-6215 ; 1940-6207
    ISSN (online) 1940-6215
    ISSN 1940-6207
    DOI 10.1158/1940-6207.CAPR-22-0080
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang